

PRESS RELEASE

OPENING OF THE FIRST EXERCISE PERIOD OF THE WARRANTS SVAS BIOSANA 2021-2024

Somma Vesuviana (NA) 28 June 2022 – Svas Biosana S.p.A. (the Company or SVAS), a leader in the healthcare sector, active in the production and distribution of medical devices intended for public and private healthcare facilities, listed on Euronext Growth Milan, communicates that the First Exercise Period of the "Warrants Svas Biosana 2021-2024" or "Warrants"- ISIN code: IT0005469157, will open on 1 July 2022.

The holders of the "Warrants Svas Biosana 2021-2024" may apply to exercise them from 1 July 2022 up to and including 29 July 2022; applications must be submitted to the broker adhering to Monte Titoli S.p.A. (Euronext Securities Milan) where the Warrants are deposited.

The Warrant holders may subscribe for newly-issued ordinary shares in Svas Biosana S.p.A. - ISIN code IT0005469264. - without par value, listed on Euronext Growth Milan (the "Converted Shares") in the ratio of 1 Converted Share per 1 Warrant held.

The Warrant exercise price, for the First Exercise Period, is Euro 14.375 per Converted Share and must be paid in full when submitting the subscription application, with no fees or expenses charged to applicants.

Subscription applications may be made on any bank business day during the First Exercise Period and must be submitted to the broker adhering to Monte Titoli S.p.A. where the Warrants are deposited.

The Converted Shares subscribed by the Warrant holders in the 1st Exercise Period will be made available for trading, via Monte Titoli S.p.A., on the settlement day following the end of the last day of the Exercise Period (29 July 2022) and shall have the same dividend entitlement as that of the Ordinary Shares traded on Euronext Growth Milan at the date of issue of the Converted Shares.

Should the Warrant holders fail to subscribe Converted Shared by the ultimate deadline of 29 July 2022, they will lose the corresponding right for the First Exercise Period, though may exercise the Warrants in each of the following Exercise Periods.

For further information, please refer to the Regulation of the "Warrants Svas Biosana 2021-2024" on the website of the Company www.svas.it, Investor Relations / Warrant Regulation section.



This press release can be found at Borsa Italiana, at the Company's registered office, and in the *Financial Releases* section of the company's website www.svas.it.

Svas Biosana uses the eMarket SDIR system, managed by Spafid Connect S.p.A., with registered office at Foro Buonaparte 10, Milan (www.emarketstorage.com), to disclose regulated information.

* * * * * * * *

Contacts:

SVAS Biosana S.p.A.

Andrea Efficace
CFO Group and Investor Relations Manager
+39 081.8995411
a.efficace@svas.it

Investor Relations Advisor

POLYTEMS HIR Bianca FERSINI MASTELLONI - Silvia MARONGIU 06.69923324-066797849 s.marongiu@polytemshir.it

Specialist

Banca Profilo +39 02.584081 **Euronext Growth Advisor**

Banca Profilo
Via Cerva 128, Milan
+39 02.584081
alessio muretti@bancaprofilo.it

Media Relations Advisor

POLYTEMS HIR
Paolo SANTAGOSTINO
+393493856585
p.santagostino@polytemshir.it

Svas Biosana manufactures and distributes medical devices in Italy and abroad. Founded in 1972 in Somma Vesuviana (NA) by the Perillo family, SVAS is now an international company with a catalogue of approximately 16,000 own and third party brand products, roughly 370 employees, a Research and Development department, 3 production facilities in Italy and subsidiaries in Slovenia, Croatia, Serbia and Bosnia-Herzegovina.

Ticker: ISIN Ordinary Shares: IT0005469264 Ticker: ISIN Warrant SVAS BIOSANA 2021-2024: IT0005469157

Companies Register of Naples no. 4543/85 Economic and Tax Code 04720630633 VAT no. 01354901215 Via M. Perillo, 34 80047 San Giuseppe Vesuviano (NA) Italy

80049 Somma Vesuviana (NA) Italy

80049 Somma Vesuviana (NA) Italy

Contacts

Tel. +390818995411 Fax +390818993922 www.svas.it

svasbiosana@legalmail.it